Radiopharmaceuticals and Tracers

This channel includes news and new technology innovations for nuclear and molecular imaging agents, radiotracers and radiopharmaceuticals used in PET or SPECT imaging. This includes advances in myocardiac perfusion agents.

neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016

June 23, 2016 — Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering...

pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016

June 20, 2016 — An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting...

SNMMI, Image of the Year 2016, PET, Alzheimer's disease, amyloid plaques

Topographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer’s disease

Right lateral surface of projected z-score images, reflecting deviation from healthy controls

Yellow/red: higher uptake, blue: lower uptake as compared to controls

Image courtesy of G. Bischof, J. Hammes, T. van Eimeren, A. Drzezga, Multimodal Neuroimaging Group, Dept. of Nuclear Medicine, University of Cologne; B. Neumaier, Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne; J. Dronse, O. Onur, J. Kukolja, G. Fink, F. Jessen, Center for Memory Disorders, Depts. of Neurology & Psychiatry, University of Cologne; and K. Fliessbach, Dept. of Neurology, University of Bonn.

Feature | PET Imaging | June 20, 2016
News | Prostate Cancer | June 17, 2016

June 17, 2016 — Decatur Memorial Hospital, Decatur, Ill., is now offering C-11 choline...

Michael J. Fox Foundation, MJFF, Parkinson's, PET tracer, competition, SNMMI 2016
News | PET Imaging | June 14, 2016

June 14, 2016 — The Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a...

PET-CT study, alcoholic brain, SNMMI 2016, mGluR5 receptor

Decreased mGluR5 availability in the brain of alcohol dependent individuals compared to healthy subjects. Image courtesy of Department of Nuclear Medicine and Molecular Imagine UZ Leuven, Leuven, Belgium

News | PET-CT | June 13, 2016

June 13, 2016 — An emerging molecular...

Loma Linda University, Siemens PETNET Solutions, PET facility, production and research
News | Nuclear Imaging | June 09, 2016

June 9, 2016 – Loma Linda University and Siemens’ PETNET Solutions Inc. have completed and brought operational a...

nuclear medicine, global market, radiopharmaceuticals, MEDraysintell, SNMMI 2016
News | Nuclear Imaging | June 08, 2016

June 8, 2016 — MEDraysintell estimates that the global market for...

NaF-PET/CT, sodium fluoride, advanced prostate cancer, metastases, pilot study
News | PET-CT | June 07, 2016

June 7, 2016 — A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium...

Axumin, fluciclovine F-18 injection, PET imaging agent, recurrent prostate cancer, Blue Earth Diagnostics, Siemens PETNET Solutions
Technology | Radiopharmaceuticals and Tracers | June 07, 2016

June 7, 2016 — Blue Earth Diagnostics Ltd. and Siemens’ PETNET Solutions Inc. announced the commercial availability...

PET, PET imaging, PET-CT, FDG PET, PET cancer assessment

A PET-CT head and neck cancer scan showing various image reconstructions. The top left image is the separate CT scan showing the anatomy. The top right scan shows the fused PET and CT scans with false color added to help interpret the image. The bottom left scan is an initial FDG PET image showing tracer hot spots in the neck and a lymph node in the right jaw due to cancer. The right bottom image is a delayed enhancement scan showing tracer uptake over time, with normal hot spots in the bladder, kidneys, testicles and brain, which normally have higher metabolic activity. The low-grade gray shading of the anatomy is due to the normal cellular metabolism uptake of the FDG throughout the body. 

Feature | PET Imaging | June 03, 2016 | Dave Fornell

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that...

Blue Earth Diagnostics, U.S. headquarters, management expansion, PET imaging agent
News | Radiopharmaceuticals and Tracers | May 13, 2016

May 13, 2016 — Blue Earth Diagnostics, a molecular imaging diagnostics company, announced it has established...

News | Radiopharmaceuticals and Tracers | May 13, 2016

May 13, 2016 — NorthStar Medical Radioisotopes LLC is enhancing its production operations at the University of...

tau protein, Alzheimer's, PET scan, imaging agent, brain decline, Washington University in St. Louis

A study using a new PET imaging agent shows that measures of tau protein in the brain more closely track cognitive decline due to Alzheimer's disease compared with long-studied measures of amyloid beta. More red color indicates more tau protein. The image on the left shows the average tau accumulation in the brains of cognitively normal people, averaged over many individuals. The image on the right shows the average amount of tau buildup in the brains of multiple people with mild Alzheimer's symptoms. Scanning multiple individuals shows that the intensity of tau deposits correlates with the severity of cognitive dysfunction. Image courtesy of Matthew R. Brier.

News | PET Imaging | May 12, 2016

May 12, 2016 — A buildup of plaque and dysfunctional proteins in the brain are hallmarks of Alzheimer’s disease....

News | Radiopharmaceuticals and Tracers | May 11, 2016

May 11, 2016 — ITM (Isotopen Technologien München AG), a specialized radiopharmaceutical company, announced that the...

News | Radiopharmaceuticals and Tracers | May 09, 2016

May 9, 2016 — A recent study demonstrates that Ga-68 DOTATATE...

PET imaging, cancer treatment, UCLA study, Caius Radu, dCK
News | PET Imaging | March 29, 2016

March 29, 2016 —A promising new discovery by University of California Los Angeles (UCLA) scientists could lead to a...

IBA, sale, IBA Molecular, proton therapy, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | March 29, 2016

March 29, 2016 — IBA (Ion Beam Applications S.A.) announced the sale of IBA Molecular (IBAM) in which IBA had a 40...

MRI, fluorine tracer agent, UC San Diego, Eric Aherns
News | Magnetic Resonance Imaging (MRI) | March 14, 2016

March 14, 2016 — Writing in the March 14 online issue of Nature Materials, researchers at University of California,...